← Leaderboards
Glen Palmer
Lsu Health Sciences Center
$8,742,380
Attributed
$8,742,380
Total exposure
10
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,742,380 · 10
By mechanism
R01$4,966,250 · 2
R33$1,458,000 · 1
R21$1,258,122 · 3
P20$691,531 · 3
R56$368,477 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Candida Albicans”
- Alexander D Johnson · University Of California San Francisco$23,545,370
- Aaron P Mitchell · La Biomed Res Inst/ Harbor Ucla Med Ctr$20,872,115
- Gavin J Sherlock · Stanford University$18,218,461
- Jay B Jackson · Johns Hopkins University$17,529,470
- Scott G Filler · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center$14,524,347
- Gerald R Fink · Whitehead Institute For Biomedical Res$14,278,186
Research focus
Candida AlbicansLifeMouse ModelMycosesAntifungal AgentsToxic EffectAntifungal TherapyResistanceIn VitroCryptococcus NeoformansSubcutaneousInfectionMortalityPatient-Focused OutcomesFungusMolecularMucous MembranePharmaceutical PreparationsIncidenceLeadGrowthCandidaCause Of DeathBase
Grant awards (24)
Antifungal antagonism as a cause of treatment failure for invasive mycoses$615,995
R01 · FY2025 · AI · contact PI
Antifungal antagonism as a cause of treatment failure for invasive mycoses$611,435
R01 · FY2024 · AI · contact PI
Antifungal antagonism as a cause of treatment failure for invasive mycoses$608,395
R01 · FY2023 · AI · contact PI
Antifungal antagonism as a cause of treatment failure for invasive mycoses$608,395
R01 · FY2022 · AI · contact PI
Broad spectrum antifungals targeting fatty acid biosynthesis$477,999
R33 · FY2022 · AI · contact PI
Examining the importance of folate biosynthetic enzymes in infectious fungi$190,000
R21 · FY2022 · AI · contact PI
Antifungal antagonism as a cause of treatment failure for invasive mycoses$618,355
R01 · FY2021 · AI · contact PI
Examining the importance of folate biosynthetic enzymes in infectious fungi$228,000
R21 · FY2021 · AI · contact PI
Broad spectrum antifungals targeting fatty acid biosynthesis$1
R33 · FY2021 · AI · contact PI
Broad spectrum antifungals targeting fatty acid biosynthesis$483,500
R33 · FY2020 · AI · contact PI
Broad spectrum antifungals targeting fatty acid biosynthesis$496,500
R33 · FY2019 · AI · contact PI
Molecular and chemical validation of the vacuole as a new antifungal target$375,123
R01 · FY2018 · AI · contact PI
Broad spectrum antifungals targeting fatty acid biosynthesis$297,622
R21 · FY2018 · AI · contact PI
Molecular and chemical validation of the vacuole as a new antifungal target$375,123
R01 · FY2017 · AI · contact PI
Broad spectrum antifungals targeting fatty acid biosynthesis$152,000
R21 · FY2017 · AI · contact PI
Molecular and chemical validation of the vacuole as a new antifungal target$375,123
R01 · FY2016 · AI · contact PI
Molecular and chemical validation of the vacuole as a new antifungal target$400,729
R01 · FY2015 · AI · contact PI
Molecular and chemical validation of the vacuole as a new antifungal target$377,577
R01 · FY2014 · AI · contact PI
A New Class of Broad Spectrum Antifungal Agents$177,500
R21 · FY2013 · AI · contact PI
Molecular and chemical validation of the vacuole as a new antifungal agent$368,477
R56 · FY2012 · AI · contact PI
A New Class of Broad Spectrum Antifungal Agents$213,000
R21 · FY2012 · AI · contact PI
ROLE OF VACUOLE EXPANSION IN THE ORAL PATHOGEN CANDIDA ALBICANS$273,549
P20 · FY2008 · RR · contact PI
ROLE OF VACUOLE EXPANSION IN THE ORAL PATHOGEN CANDIDA ALBICANS: HIV$263,870
P20 · FY2007 · RR · contact PI
ROLE OF VACUOLE EXPANSION IN THE ORAL PATHOGEN CANDIDA ALBICANS: HIV$154,112
P20 · FY2006 · RR · contact PI